登录    
  
首页 > 期刊论文 > 论文摘要
人肺腺癌吉非替尼耐药细胞株中微小RNA的表达谱
         
microRNA expression profiles in acquired gefitinib-resistant human lung adenocarcinoma cell line PC9/AB2vs its parental cell line PC9

摘    要
目的:分析人肺腺癌吉非替尼耐药细胞株PC9/AB2与亲本细胞株PC9中微小RNA(microRNA,miRNA)表达谱的差异。方法:应用Agilent human miRNA芯片分别检测PC9/AB2细胞与PC9细胞miRNA的表达谱,随后采用Agilent Feature Extraction软件分析并筛选差异表达的miRNA,应用生物信息软件预测筛选出的差异表达miRNA的潜在靶基因。应用实时荧光定量-PCR(real-time fluorogenic quantitative-PCR,RFQ-PCR)验证芯片检测结果。结果:与PC9细胞比较,PC9/AB2细胞中有36个miRNA表达上调>2倍,有24个miRNA表达下调>2倍。RFQ-PCR验证了芯片的结果。软件预测发现,16个miRNA有潜在靶基因,其中11个miRNA的靶基因>100个。结论:筛选获得的差异表达miRNA可能通过调控其靶基因而参与人肺腺癌细胞对吉非替尼的耐药。
标    签 肺肿瘤   抗药性   肿瘤   微RNAs   微阵列分析   吉非替尼   Lung neoplasms   Drug resistance   neoplasm   MicroRNAs   Microarray analysis   Gefitinib  
 
Abstract
Objective: To identify the differential expression of microRNAs(miRNAs) in acquired gefitinib-resistant human lung adenocarcinoma cell line PC9/AB2versus parental cell line PC9. Methods: The expression profiles of PC9/AB2 and PC9 cells were detected by using Agilent Human microRNA Microarray. The Agilent Feature Extraction software was used to analyze the differential expression of miRNA, and the Bioinformatics software was used to predict the potential target genes of differentially expressed miRNAs. The real-time fluorescenic quantitative-PCR(RFQ-PCR) was used to confirm the result of microRNA microarray. Results: There were thirty-six miRNAs up-regulated over 2-fold and twenty-four miRNAs down-regulated over 2-fold in PC9/AB2 cells as compared with those in PC9 cells. The result of microRNA microarray was validated by RFQ-PCR. The prediction result revealed that 16 miRNAs had their potential target genes, and 11 of which had the potential target genes over 100. Conclusion: The differential expression of miRNAs may be contributed to acquired gefitinib-resistance of human lung adenocarcinoma cells by regulating their target genes.

中图分类号 R734.2   DOI 10.3781/j.issn.1000-7431.2012.01.003

 
  购买该论文  中国光学期刊网论文下载说明
      


所属栏目 基础研究

基金项目 国家自然科学基金资助项目(编号:30873023)

收稿日期 2011/8/12

修改稿日期 2011/10/24

网络出版日期

作者单位点击查看


引用该论文: WANG Yong-sheng,ZHANG Jie,CHEN Mo,LI Bing,KUANG Peng,LI Jia-yu,REN Sheng-xiang,TANG Liang,ZHOU Cai-cun. microRNA expression profiles in acquired gefitinib-resistant human lung adenocarcinoma cell line PC9/AB2vs its parental cell line PC9[J]. Tumor, 2012, 32(1): 16~20
王永生,张颉,陈墨,李冰,况鹏,李嘉瑜,任胜祥,唐亮,周彩存. 人肺腺癌吉非替尼耐药细胞株中微小RNA的表达谱[J]. 肿瘤, 2012, 32(1): 16~20


被引情况:


【1】李静,武新虎,刘志冰,王振,宋勇,朱锡旭, "阿法替尼联合西妥昔单抗治疗非小细胞肺癌EGFR T790M突变所致的吉非替尼耐药",肿瘤 33, 619-623(2013)



论文评价
共有人对该论文发表了看法,其中:
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好
分享论文
分享到新浪微博 分享到腾讯微博 分享到人人网 分享到 Google Reader 分享到百度搜藏分享到Twitter

参考文献
【1】JEMAL A, SIEGEL R, XU J, et al. Cancer statistics,2010[J]. CA Cancer J Clin, 2010, 60(5):277-300.
 
【2】SHE PHE RD F A, RODRIGUES PEREIRA J,CIULEANU T, et al. Erlotinib in previously treatednon-small cell lung cancer[J]. N Engl J Med, 2005,353(2):123-132.
 
【3】ZHOU C, WU Y L, CHEN G, et al. Erlotinib versuschemotherapy as first-line treatment for patientswith advanced EGFR mutation-positive nonsmallcell lung cancer (OPTIMAL, CTONG-0802):a multicentre, open-label, randomised, phase 3study[J]. Lancet Oncol, 2011, 12(8):735-742.
 
【4】JACKMAN D, PAO W, RIELY G J, et al. Clinicaldefinition of acquired resistance to epidermalgrowth factor receptor tyrosine kinase inhibitorsin non-small cell lung cancer[J]. J Clin Oncol,2010, 28(2):357-360.
 
【5】ROYBAL J D, ZANG Y, AHN Y H, et al. miR-200Inhibits lung adenocarcinoma cell invasion andmetastasis by targeting Flt1/VEGFR1[J]. MolCancer Res, 2011, 9(1):25-35.
 
【6】ESQUELA-KERSCHER A, TRANG P, WIGGINS J F,et al. The let-7 microRNA reduces tumor growthin mouse models of lung cancer[J]. Cell Cycle,2008, 7(6):759-764.
 
【7】JU L, ZHOU C, LI W, et al. Integrin beta1 overexpressionassociates with resistance totyrosine kinase inhibitor gefitinib in nonsmallcell lung cancer[J]. J Cell Biochem, 2010,111(6):1565-1574.
 
【8】PAO W, MILLER V A, POLITI K A, et al. Acquiredresistance of lung adenocarcinomas to gefitinibor erlotinib is associated with a second mutationin the EGFR kinase domain[J]. PLoS Med, 2005,2(3):e73.
 
【9】KOSAKA T, YATABE Y, ENDOH H, et al. Analysis ofepidermal growth factor receptor gene mutationin patients with non-small cell lung cancer andacquired resistance to gefitinib[J]. Clin CancerRes, 2006, 12(19):5764-5769.
 
【10】ENGELMAN J A, ZEJNULLAHU K, MITSUDOMI T, et al.MET amplification leads to gefitinib resistancein lung cancer by activating ERBB3 signaling[J].Science, 2007, 316(5827):1039-1043.
 
【11】CALIN G A, DUMITRU C D, SHIMIZU M, et al.Frequent deletions and down-regulation ofmicro-RNA genes miR15 and miR16 at 13q14 inchronic lymphocytic leukemia[J]. Proc Natl AcadSci U S A, 2002, 99(24):15524-15529.
 
【12】BLOWER P E, CHUNG J H, VERDUCCI J S, et al.MicroRNAs modulate the chemosensitivity oftumor cells[J]. Mol Cancer Ther, 2008, 7(1):1-9.
 
【13】DAI Y, XIE C H, NEIS J P, et al. MicroRNAexpression profiles of head and neck squamouscell carcinoma with docetaxel-induced multidrugresistance[J]. Head Neck, 2010, 33(6):786-791.
 
【14】陈 勇, 左 静, 刘 颖, 等. miRNA-200c 逆转胃癌SGC7901/DDP 细胞对顺铂的耐药性及其相关机制[J].肿瘤, 2010, 30(8):646-650.
 
【15】YANG H, KONG W, HE L, et al. MicroRNAexpression profiling in human ovarian cancer:miR-214 induces cell survival and cisplatinresistance by targeting PTEN[J]. Cancer Res, 2008,68(2):425-433.
 
【16】PAN X, WANG Z X, WANG R. MicroRNA-21:a noveltherapeutic target in human cancer[J]. Cancer BiolTher, 2011, 10(12):1224-1232.
 
【17】CHOU Y T, LIN H H, LIEN Y C, et al. EGFR promoteslung tumorigenesis by activating miR-7 througha Ras/ERK/Myc pathway that targets the Ets2transcriptional repressor ERF[J]. Cancer Res, 2010,70(21):8822-8831.
 
相关信息
   标题 相关频次
 表皮生长因子受体基因CA简单重复序列多态性与晚期小细胞肺癌患者表皮生长因子受体酪氨酸激酶抑制剂临床疗效间的关系
 12
 吉非替尼耐药细胞株的筛选和基因谱表达研究
 10
 培美曲塞治疗非小细胞肺癌无症状脑转移临床分析
 10
 人肺腺癌细胞株A549和A549/DDP的比较蛋白质组学研究
 10
 微RNA-21与BIM蛋白在逆转肺腺癌细胞对EGFR-TKIs耐药中的相互拮抗作用
 8
 蟾毒灵逆转肺腺癌H1975细胞对吉非替尼耐药的体内实验研究
 7
 胸苷酸合酶基因变数串联重复多态性与培美曲塞治疗晚期非小细胞肺癌疗效相关性分析
 7
 KDR基因重组的T7噬菌体疫苗构建及其对小鼠Lewis肺癌抑制作用的研究
 6
 miR-19a对非小细胞肺癌细胞组织因子的调控作用及细胞增殖的影响
 6
 厄洛替尼治疗晚期非小细胞肺癌的临床研究
 6
 干细胞标志CD90与人肺腺癌A549细胞顺铂耐药之间的关系
 6
 核仁磷酸蛋白和c-Src在耐药肺腺癌细胞中的表达及其与化疗耐药之间的关系
 6
 扩增阻滞突变系统法检测非小细胞肺癌微小标本表皮生长因子受体突变
 6
 硫酸基转移酶1E1基因单核苷酸多态性联合吸烟与肺癌易感性的关系
 6
 Ⅳ型胶原对耐顺铂人肺腺癌细胞化疗诱导凋亡的影响
 5
 表皮生长因子受体信号通路与卵巢癌耐药细胞株SKOV3/DDP相关性的研究
 5
 非小细胞肺癌组织表皮生长因子受体基因突变的临床意义
 5
 空洞型肺鳞癌与非空洞型肺鳞癌的临床特征分析
 5
 血管内皮生长因子C过表达或抑制表达对人小细胞肺癌NCI-H446细胞生物学行为的影响
 5
 DNA修复基因MMS19单核苷酸多态性与非小细胞肺癌组织学类型的关系
 4
 ERCC1、RRM1和BRCA1在非小细胞肺癌中的表达及预后意义
 4
 H2O2氧化刺激对紫杉醇耐药和敏感肺癌细胞的不同影响
 4
 H101溶瘤腺病毒联合长春瑞滨/顺铂一线治疗晚期非小细胞肺癌
 4
 RNA干扰抑制Apollon表达联合川芎嗪可增强白血病细胞对化疗药物的敏感性
 4
 靶向肺癌的紫杉醇长循环脂质体抑瘤作用研究
 4
 靶向血管新生肽修饰的氧化铁纳米粒对荷瘤裸鼠磁热疗的研究
 4
 靶向肿瘤新生血管的顺磁性纳米脂质体在MRI诊断肺癌中的研究
 4
 长程多柔比星化疗富集乳腺肿瘤干细胞
 4
 非小细胞肺癌患者EGFR基因突变状态影响因素的临床分析
 4
 肺癌中DNA甲基化对微RNA调控作用的研究进展
 4

  热点专题


关于我们  |   联系我们  |   广告投放  |   《肿瘤》杂志社版权所有 《肿瘤》杂志社   © 中国 上海 2014.3
沪ICP备15036656号-2